Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;85(3):207-214.
doi: 10.1016/j.eururo.2023.11.013. Epub 2023 Dec 1.

Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men

Ola Bratt  1 , Rebecka Arnsrud Godtman  2 , Thomas Jiborn  3 , Jonas Wallström  4 , Olof Akre  5 , Stefan Carlsson  5 , Tobias Nordström  6 , Erik Thimansson  7 , Max Alterbeck  8 , Sophia Zackrisson  9 , Jonas Hugosson  2 , Anders Bjartell  8 , Anna Lantz  10
Affiliations
Free article

Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men

Ola Bratt et al. Eur Urol. 2024 Mar.
Free article

Abstract

Background: The European Union recently recommended evaluation of the feasibility of organised prostate cancer screening. In Sweden, regional population-based organised prostate cancer testing (OPT) programmes were introduced in 2020.

Objective: To describe initial participation rates and diagnostic outcomes.

Design, setting, and participants: The three most populated Swedish regions invited all men aged 50 yr to OPT by a letter in 2020-2022. Men with prostate-specific antigen (PSA) ≥3 ng/ml were referred for prostate magnetic resonance imaging (MRI). PSA assays differed across regions. Men with Prostate Imaging Reporting and Data System (PI-RADS) 1-3 and PSA density ≥0.15 ng/ml/cm3 or PI-RADS 4-5 were referred for a biopsy. Data were obtained from the Swedish Register for Organised Prostate Cancer Testing.

Outcome measurements and statistical analysis: Overall and regional participation rates, PSA distributions, PI-RADS score distributions, cancer detection, and treatment were evaluated.

Results and limitations: A total of 23 855 (35%) of 68 060 invited men participated; 696 (2.9%) had PSA ≥3 ng/ml, and of them, 306 (44%) had a biopsy indication and 221 (32%) had a biopsy. On biopsy, 93 (42%) had Gleason grade group ≥2 (0.39% of PSA-tested men) and 44 (20%) Gleason grade group 1 cancer. Most men with cancer had treatment with curative intent (70%) or were under active surveillance (28%). Across regions, proportions of men with PSA ≥3 ng/ml ranged from 2.3% to 4.0%, and those with PI-RADS score 4-5 ranged from 12% to 21%. A limitation is that results are applicable only to first testing of men in their early 50s.

Conclusions: The OPT programmes are feasible with good compliance to the diagnostic pathway. The use of MRI and PSA density avoided a biopsy for over half of the men with PSA ≥3 ng/ml. Inter-regional differences in diagnostic outcomes show a need for standardisation of the diagnostic pathway's components.

Patient summary: We report the diagnostic outcomes of inviting 68 000 50-yr-old men to organised prostate cancer testing.

Keywords: Early detection; Population; Prostate cancer; Prostate-specific antigen; Screening.

PubMed Disclaimer

Substances